Latest News

BerGenBio plans IPO and partners with MSD

To activate the Axl kinase and transmit its signal to the cell nucleus, the GAS6 ligand has to bind externally and the energy carrier ATP (green) internally. Inhibitors (orange) prevent transmission of the signal, © MPI for Biochemistry


by tg

Norwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Merck’s PD-1 inhibitor pembrolizumab in lung cancer patients.

The IPO, underwritten by ABG Sundal Collier, Arctic Securities and DNB Markets, includes a public offering to institutional and retail investors in Norway and Sweden, and a private placement to certain institutional investors internationally.

BerGenBio’s lead candidate BGB324 (formerly R-428), licensed from Rigel Pharmaceuticals in 2010, has passed Phase Ib testing in acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), and non-small cell lung cancer (NSCLC, in combination with erlonitib) patients. On the day of the IPO announcement, BerGenBio additionally said it will start two collaborative Phase II combination studies of BGB324 with Merck & Co’s PD-1 checkpoint inhibitor pembrolizumab this year in patients with adenocarcinoma (NSCLC) and and triple-negative breast cancer (TNBC). The clinical trials will be sponsored by BerGenBio while Merck will provide the trial with Keytruda. The rights to the study results will be shared. Financial details were not disclosed. Preclinical data from 2015 indicate that BGB324 showed enhanced tumour clearance, survival and tumour infiltration of cytotoxic T lymphocytes compared with checkpoint inhibition (CTLA-4, PD1) alone.

Axl kinase promotes cancer cell migration, epithelial-mesenchymal transition (EMT) and tumour cell proliferation as well as therapy resistance. The protein is overexpressed in the membranes of 60% of lung cancers, highly invasive breast cancers, and pancreatic cancer as well as in AML, where it serves as independent prognostic marker. Additionally, several studies suggest that overexpression of AXL may result in resistance to both targeted therapies and conventional chemotherapy in different models, such as lung cancer, breast cancer resistant to EGFR inhibition, esophageal carcinoma, gastrointestinal stromal tumours, and AML. 

Besides its selective Axl kinase inhibitor, the Norwegian company also has an anti-Axl kinase antibody and an antibody drug conjugate (ADC) under preclinical development. Treatment responders are set to be stratified prior to therapy by a companion diagnostics test that measures Axl kinase expression.

EU orders additional COVID-19 vaccine doses

Under the new deal, the Commission has the option to request supply of an additional 100 million doses. This new agreement is in addition to the 300...

LSP leads €21m round into Neurent Medical

Galway-based medical device company Neurent Medical, which is focussed on chronic inflammatory diseases of the sinuses and nasal passages said it...

Valneva in talks with EU about 60 million vaccine doses

VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

PCR-test reveals risk of genotoxity of genome editing

The new method called single targeted linker-mediated PCR sequencing (CAST-Seq), developed at University Hospital Freiburg, Germany, is set to become...

B.1.1.7 variant associated with higher mortality

Previous reports from British autorities that suggested a 30 to 100% higher mortality of B.1.1.7 than of the previously dominant form in Europe are...

Oxular Ltd raises US$37m

Oxford-based Oxular said it will use the proceeds to finance Phase II studies evaluatingO the company’s lead asset, OXU-001, for the treatment of...

Janssen to pledge COVID-19 vaccine to African Union

The announcement follows a contract signed last year with the global vaccine alliance Gavi to deliver up to 500 million doses of JNJ’ adenoviral...